<DOC>
	<DOCNO>NCT00949650</DOCNO>
	<brief_summary>This randomise , open label phase III trial perform patient adenocarcinoma lung tumour harbour Epidermal Growth Factor Receptor activate mutation . The objective trial compare efficacy single agent BIBW 2992 , Arm A , Pemetrexed/Cisplatin chemotherapy , Arm B , first line treatment group patient .</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) Versus Chemotherapy First Line Treatment NSCLC With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : Pathologically confirm diagnosis Stage IIIB ( cytologically proven pleural effusion pericardial effusion ) Stage IV adenocarcinoma lung . Patients mixed histology eligible adenocarcinoma predominant histology . Epidermal Growth Factor Receptor mutation detect central laboratory analysis tumour biopsy material . Measurable disease accord RECIST 1.1 . Eastern Cooperative Oncology Group score 0 1 . Age &gt; /= 18 year . Life expectancy least three month . Written inform consent consistent ICHGCP guideline . Exclusion criterion : Prior chemotherapy relapse and/or metastatic NSCLC . Neoadjuvant/adjuvant chemotherapy permit least 12 month elapse end chemotherapy randomisation . Prior treatment Epidermal Growth Factor Receptor target small molecule antibody . Radiotherapy surgery ( biopsy ) within 4 week prior randomisation . Active brain metastasis Any current malignancy malignancy diagnose within past five year Known preexist interstitial lung disease . Significant recent acute gastrointestinal disorder diarrhoea major symptom . History presence clinically relevant cardiovascular abnormality . Any concomitant serious illness organ system dysfunction . Adequate absolute neutrophil count platelet count Adequate liver kidney function Active hepatitis B infection , active hepatitis C infection know HIV carrier .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>